ABNOM
☆ AI Dermatology — Free Service
En los resultados de 2022 del Stiftung Warentest de Alemania, la satisfacción del consumidor con ModelDerm fue sólo ligeramente inferior que con las consultas de telemedicina pagadas.
En los resultados de 2022 del Stiftung Warentest de Alemania, la satisfacción del consumidor con ModelDerm fue sólo ligeramente inferior que con las consultas de telemedicina pagadas.
relevance score : -100.0%
ReferencesSe sabe que el láser Q‑switched Nd:YAG trata eficazmente el nevo de Ota y afecciones similares. Realizamos un estudio para evaluar la eficacia de un láser de alta fluencia de 1064 nm Q‑switched Nd:YAG en manchas mongólicas ubicadas en áreas inusuales, sin aclarar la piel. Estudiamos a 61 pacientes con estas manchas, analizando un total de 70 lesiones. La mitad de las lesiones se trataron con láser, mientras que el resto se dejó sin tratar para servir de control. Evaluamos los resultados mediante una escala de puntuación y con un dispositivo llamado Mexameter® para medir los niveles de melanina. Los pacientes fueron seguidos durante un promedio de 14 meses en el grupo tratado y 18 meses en el grupo de observación. Al final del estudio, se observaron diferencias significativas en las puntuaciones de la escala y en los niveles de melanina entre los grupos tratado y no tratado, y el grupo tratado con láser mostró mejores resultados. El láser de alta fluencia Q‑switched Nd:YAG, sin aclarar la piel, demostró ser eficaz y seguro para tratar estas inusuales manchas mongólicas.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Estudiamos la eficacia y seguridad de un tratamiento con láser específico para ABNOM y analizamos los factores que podrían influir en su efectividad. Evaluamos a 110 pacientes diagnosticados con ABNOM que recibieron entre dos y nueve sesiones de láser. Descubrimos que el tratamiento funcionó mejor cuanto más prolongado fue, pero mostró menor eficacia en pacientes de mayor edad. También obtuvo mejores resultados en pacientes con piel más clara (tipo III) y áreas afectadas más pequeñas (menos de 10 cm²). La presencia de melasma junto con ABNOM redujo la efectividad del tratamiento. El color o la cantidad de áreas afectadas no parecieron marcar diferencia. Aproximadamente el 10 % de los pacientes desarrollaron manchas más oscuras después del procedimiento. El tratamiento múltiple temprano dio buenos resultados. Los pacientes mayores con piel más oscura y manchas preexistentes tienen mayor probabilidad de presentar hiperpigmentación post‑tratamiento. Para los pacientes con ABNOM y melasma, es preferible utilizar un láser de menor energía para evitar que el melasma empeore.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Tratamiento
Los agentes despigmentantes rara vez son eficaces. A diferencia del melasma, la ABNOM puede mejorar con terapia láser y, una vez tratada, no suele recaer. Se pueden realizar de 10 a 20 sesiones de láser para tratar la ABNOM.
#QS1064 laser